5/120
0.2 / 5 stars
All 120 Win/Lose results shown below
ANRO Roast Me summary
Alto Neuroscience, Inc. (ANRO). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinANRO / S&P 17.39% / 15.20% |
LoseANRO / S&P ANRO unavailable / 15.00% |
LoseANRO / S&P ANRO unavailable / 50.40% |
| 2026-Q11/3 |
WinANRO / S&P 26.29% / -4.33% |
LoseANRO / S&P ANRO unavailable / 11.30% |
LoseANRO / S&P ANRO unavailable / 27.70% |
| 2025-Q41/3 |
WinANRO / S&P 342.79% / 2.65% |
LoseANRO / S&P ANRO unavailable / 9.00% |
LoseANRO / S&P ANRO unavailable / 13.40% |
| 2025-Q31/3 |
WinANRO / S&P 82.73% / 8.12% |
LoseANRO / S&P ANRO unavailable / 4.61% |
LoseANRO / S&P ANRO unavailable / 13.45% |
| 2025-Q20/3 |
LoseANRO / S&P 1.85% / 10.94% |
LoseANRO / S&P ANRO unavailable / 4.83% |
LoseANRO / S&P ANRO unavailable / 10.63% |
| 2025-Q10/3 |
LoseANRO / S&P -48.94% / -4.27% |
LoseANRO / S&P ANRO unavailable / 4.98% |
LoseANRO / S&P ANRO unavailable / 10.57% |
| 2024-Q40/3 |
LoseANRO / S&P -63.02% / 2.41% |
LoseANRO / S&P ANRO unavailable / 5.25% |
LoseANRO / S&P ANRO unavailable / 6.15% |
| 2024-Q31/3 |
WinANRO / S&P 7.02% / 5.89% |
LoseANRO / S&P ANRO unavailable / 5.89% |
LoseANRO / S&P ANRO unavailable / 6.11% |
| 2024-Q20/3 |
LoseANRO / S&P -30.36% / 4.28% |
LoseANRO / S&P ANRO unavailable / 5.38% |
LoseANRO / S&P ANRO unavailable / 5.12% |
| 2024-Q10/3 |
LoseANRO / S&P ANRO unavailable / 10.56% |
LoseANRO / S&P ANRO unavailable / 5.71% |
LoseANRO / S&P ANRO unavailable / 5.59% |
| 2023-Q40/3 |
LoseANRO / S&P ANRO unavailable / 11.69% |
LoseANRO / S&P ANRO unavailable / 6.81% |
LoseANRO / S&P ANRO unavailable / 7.78% |
| 2023-Q30/3 |
LoseANRO / S&P ANRO unavailable / -3.27% |
LoseANRO / S&P ANRO unavailable / 7.52% |
LoseANRO / S&P ANRO unavailable / -5.03% |
| 2023-Q20/3 |
LoseANRO / S&P ANRO unavailable / 8.74% |
LoseANRO / S&P ANRO unavailable / 9.50% |
LoseANRO / S&P ANRO unavailable / -8.57% |
| 2023-Q10/3 |
LoseANRO / S&P ANRO unavailable / 7.50% |
LoseANRO / S&P ANRO unavailable / 10.77% |
LoseANRO / S&P ANRO unavailable / -15.69% |
| 2022-Q40/3 |
LoseANRO / S&P ANRO unavailable / 7.56% |
LoseANRO / S&P ANRO unavailable / 11.88% |
LoseANRO / S&P ANRO unavailable / -17.99% |
| 2022-Q30/3 |
LoseANRO / S&P ANRO unavailable / -4.88% |
LoseANRO / S&P ANRO unavailable / 13.47% |
LoseANRO / S&P ANRO unavailable / -1.41% |
| 2022-Q20/3 |
LoseANRO / S&P ANRO unavailable / -16.10% |
LoseANRO / S&P ANRO unavailable / 13.71% |
LoseANRO / S&P ANRO unavailable / 11.04% |
| 2022-Q10/3 |
LoseANRO / S&P ANRO unavailable / -4.60% |
LoseANRO / S&P ANRO unavailable / 15.97% |
LoseANRO / S&P ANRO unavailable / 42.23% |
| 2021-Q40/3 |
LoseANRO / S&P ANRO unavailable / 11.03% |
LoseANRO / S&P ANRO unavailable / 15.00% |
LoseANRO / S&P ANRO unavailable / 96.40% |
| 2021-Q30/3 |
LoseANRO / S&P ANRO unavailable / 0.58% |
LoseANRO / S&P ANRO unavailable / 10.77% |
LoseANRO / S&P ANRO unavailable / 69.42% |
| 2021-Q20/3 |
LoseANRO / S&P ANRO unavailable / 8.55% |
LoseANRO / S&P ANRO unavailable / 6.58% |
LoseANRO / S&P ANRO unavailable / 51.81% |
| 2021-Q10/3 |
LoseANRO / S&P ANRO unavailable / 6.17% |
LoseANRO / S&P ANRO unavailable / -1.06% |
LoseANRO / S&P ANRO unavailable / 7.39% |
| 2020-Q40/3 |
LoseANRO / S&P ANRO unavailable / 12.15% |
LoseANRO / S&P ANRO unavailable / -3.72% |
LoseANRO / S&P ANRO unavailable / -33.42% |
| 2020-Q30/3 |
LoseANRO / S&P ANRO unavailable / 8.93% |
LoseANRO / S&P ANRO unavailable / -2.04% |
LoseANRO / S&P ANRO unavailable / -27.10% |
| 2020-Q20/3 |
LoseANRO / S&P ANRO unavailable / 20.54% |
LoseANRO / S&P ANRO unavailable / -0.46% |
LoseANRO / S&P ANRO unavailable / -27.11% |
| 2020-Q10/3 |
LoseANRO / S&P ANRO unavailable / -19.60% |
LoseANRO / S&P ANRO unavailable / 3.47% |
LoseANRO / S&P ANRO unavailable / -14.75% |
| 2019-Q40/3 |
LoseANRO / S&P ANRO unavailable / 9.07% |
LoseANRO / S&P ANRO unavailable / 5.36% |
LoseANRO / S&P ANRO unavailable / 2.99% |
| 2019-Q30/3 |
LoseANRO / S&P ANRO unavailable / 1.70% |
LoseANRO / S&P ANRO unavailable / 5.02% |
LoseANRO / S&P ANRO unavailable / 0.21% |
| 2019-Q20/3 |
LoseANRO / S&P ANRO unavailable / 4.30% |
LoseANRO / S&P ANRO unavailable / 6.64% |
LoseANRO / S&P ANRO unavailable / 8.65% |
| 2019-Q10/3 |
LoseANRO / S&P ANRO unavailable / 13.65% |
LoseANRO / S&P ANRO unavailable / 8.12% |
LoseANRO / S&P ANRO unavailable / 14.29% |
| 2018-Q40/3 |
LoseANRO / S&P ANRO unavailable / -13.52% |
LoseANRO / S&P ANRO unavailable / 9.05% |
LoseANRO / S&P ANRO unavailable / 18.23% |
| 2018-Q30/3 |
LoseANRO / S&P ANRO unavailable / 7.71% |
LoseANRO / S&P ANRO unavailable / 10.21% |
LoseANRO / S&P ANRO unavailable / 19.06% |
| 2018-Q20/3 |
LoseANRO / S&P ANRO unavailable / 3.43% |
LoseANRO / S&P ANRO unavailable / 9.03% |
LoseANRO / S&P ANRO unavailable / 14.46% |
| 2018-Q10/3 |
LoseANRO / S&P ANRO unavailable / -0.76% |
LoseANRO / S&P ANRO unavailable / 7.68% |
LoseANRO / S&P ANRO unavailable / 12.46% |
| 2017-Q40/3 |
LoseANRO / S&P ANRO unavailable / 6.64% |
LoseANRO / S&P ANRO unavailable / 7.03% |
LoseANRO / S&P ANRO unavailable / 13.82% |
| 2017-Q30/3 |
LoseANRO / S&P ANRO unavailable / 4.48% |
LoseANRO / S&P ANRO unavailable / 5.68% |
LoseANRO / S&P ANRO unavailable / 17.57% |
| 2017-Q20/3 |
LoseANRO / S&P ANRO unavailable / 3.09% |
LoseANRO / S&P ANRO unavailable / 4.83% |
LoseANRO / S&P ANRO unavailable / 17.74% |
| 2017-Q10/3 |
LoseANRO / S&P ANRO unavailable / 6.07% |
LoseANRO / S&P ANRO unavailable / 3.67% |
LoseANRO / S&P ANRO unavailable / 13.32% |
| 2016-Q40/3 |
LoseANRO / S&P ANRO unavailable / 3.82% |
LoseANRO / S&P ANRO unavailable / 2.09% |
LoseANRO / S&P ANRO unavailable / 7.05% |
| 2016-Q30/3 |
LoseANRO / S&P ANRO unavailable / 3.85% |
LoseANRO / S&P ANRO unavailable / 0.20% |
LoseANRO / S&P ANRO unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | ANRO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 855.52% | 20.78% |
| Annualized return | 855.52% | 20.78% |
5Y · 2024-02-02 to 2026-08-28
| Metric | ANRO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 69.87% | 83.14% |
| Annualized return | 11.18% | 12.86% |
10Y · 2024-02-02 to 2026-08-28
| Metric | ANRO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 69.87% | 319.30% |
| Annualized return | 5.44% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |